In this video, I analyze recent clinical trial findings that highlight what’s on the horizon for innovative therapies targeting APOE4 carriers and Alzheimer’s disease.

The game-changing findings:

Lecanemab (4-year data from Yale):

• 56% reduction in progression to dementia

• 69% of low-tau patients had ZERO decline after 4 years

• Safety update: 92% of ARIA happens in first 6 months, then drops to placebo levels

Donanemab (3-year data from Eli Lilly):

• Benefits DOUBLED over time (0.6 to 1.2 CDR-SB points)

• Starting 18 months earlier = 27% better outcomes

• This suggests actual disease modification, not just temporary slowing

Obicetrapib (surprise finding from Amsterdam):

• It's an oral cholesterol drug (CETP inhibitor)

• APOE4/4 carriers showed 20% reduction in P-tau217

• First oral medication showing specific benefit for E4 carriers

Reality check:
These drugs slow decline, they don't reverse existing damage. But the fact that benefits keep growing over 4 years (instead of plateauing) is huge. It suggests we're actually changing the disease trajectory.

The critical message:
If you're at risk, get tested early. The difference between starting treatment immediately vs waiting 18 months is massive.

If you are an APOE4 carriers, join us in The Phoenix Community and take action TODAY

The insights are summarized from the July 2025 Alzheimer’s Association International Conference session, Developing Topics on Innovative Therapeutic Approaches.

I do not have any affiliation with any of the companies mentioned in this video. I am an APOE4/4 carriers looking for solutions myself and sharing what I learn along the way in the Phoenix Community and occasionally with other groups.

Sources:
The insights are summarized from the July 2025 Alzheimer’s Association International Conference session, Developing Topics on Innovative Therapeutic Approaches.

Researchers in this session:
John R. Sims (Eli Lilly and Company, IN, USA) - Donanemab in Early Symptomatic Alzheimer's Disease: Efficacy and Safety from the TRAILBLAZER‐ALZ 2 Long-Term Extension

Christopher H van Dyck (Yale School of Medicine, CT, USA; Alzheimer's Disease Research Unit, Yale School of Medicine, CT, USA) - The Lecanemab Clarity AD Open-Label Extension in Early Alzheimer’s Disease: Initial Findings From the 48-Month Analysis

Hui-dong Tang (Department of Geriatrics, Medical Center on Aging of Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, China) - Microglial Activation Correlates with Amyloid Clearance and Cognitive Benefit in Lecanemab-Treated Early AD Patients

Philip Scheltens (Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Netherlands) - Effects of Obicetrapib, a Potent Oral CETP Inhibitor, on Alzheimer's Disease Biomarkers in 1727 Patients with cardiovascular disease